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Abstract Lipids, abundant constituents of both the
vascular plaque and lipoproteins, play a pivotal role in
atherosclerosis. Mass spectrometry-based analysis of
lipids, called lipidomics, presents a number of opportu-
nities not only for understanding the cellular processes in
health and disease but also in enabling personalized
medicine. Lipidomics in its most advanced form is able
to quantify hundreds of different molecular lipid species
with various structural and functional roles. Unraveling
this complexity will improve our understanding of
diseases such as atherosclerosis at a level of detail not
attainable with classical analytical methods. Improved
patient selection, biomarkers for gauging treatment
efficacy and safety, and translational models will be
facilitated by the lipidomic deliverables. Importantly,
lipid-based biomarkers and targets should lead the way
as we progress toward more specialized therapeutics.
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Introduction
Dyslipidemia and resultant atherosclerosis are believed to
stem from the imbalance of the lipid metabolites in the
affectedorganism.Tothisend,advancesinmassspectrometry
and lipid biochemistry enable the simultaneous high-
throughput identification and quantification of hundreds of
molecular lipid species in a number of lipid classes that make
up the organism’s lipidome [1￿, 2]. Lipidomic studies
quantify the precise chemical constituents of lipidomes,
identify lipid cellular distribution, and describe their bio-
chemical mechanisms, interactions and dynamics [3].
Elevated serum total cholesterol and low-density
lipoprotein cholesterol (LDL-C) have been established
as risk factors for atherosclerosis and its complications.
However, a number of coronary artery disease (CAD) or
acute myocardial infarction (AMI) patients have LDL-C
levels within the recommended range, suggesting the
need for additional diagnostic measures of the residual
risk. Lipidomics is a tool for differentiating patients
based on their molecular lipid profiles. Personalized
medicine and diagnostics enabled by lipidomics will
facilitate the mission of the right individual receiving the
right drug at the right time and dose.
Atherosclerotic plaques are the culmination points of the
vascular disease, and retracing the steps of their formation
necessitates the structural and functional understanding of
the lipoproteins carrying the putative plaque-building
blocks as well as the deciphering of the actual plaque
composition and function at various stages of its develop-
ment. Although we may be used to thinking of lipids in the
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DOI 10.1007/s11883-010-0110-ycontext of atherosclerosis as LDL-C, this is a major
oversimplification. When traditional clinical chemistry has
exhausted its resources, lipidomics provides yet another
layer deeper into the patient lipidome, unraveling distinct
biochemical characteristics. Indeed, lipidomes of eukaryotic
cells comprise hundreds to thousands of molecular lipid
species that serve as cellular building blocks (such as cell
and organelle membranes), store metabolic energy, and
function as bioactive molecules [4–6]. Also, the vascular
plaques and lipoproteins responsible for cholesterol trans-
port contain hundreds of other associated lipid species that
may exhibit various bioactive properties affecting the
course of the disease.
Lipids are physiologic end points of a biological system,
and because of their tight regulation they are prime
biomarker candidates. Lipidomics in combination with the
appropriate clinical samples and biobank material is used
today to address the many unmet needs of disease
diagnostics. In addition to prognostic and diagnostic value,
lipidomics may also find biomarkers that will serve as a
read-out of experimental or approved therapies, whereas the
appreciation for the bioactivity of lipids has the potential
for identifying novel drug targets.
Lipids are also excellent candidates for companion
diagnostics in the pharmaceutical arena, which is moving
increasingly toward the specialized therapeutics model.
Lipidomics has also been used to study translational
medicine and thereby is helpful in assessing the utility of
various experimental animal models. In this review, we
summarize the current state of lipidomics as applied to
vascular research and discuss the possibilities it presents to
us.
Lipidomics Technology
Lipidomics and Molecular Lipids
The recent development of mass spectrometry-driven lipid
analysis approaches called “lipidomics” has made it
possible to resolve complex lipidomes to their molecular
lipid species level at high-throughput and quality required
for analyses of clinical cohorts [1￿, 7, 8]. As a result of the
high sensitivity and selectivity of the methods, a lipidome-
wide analysis of minute sample amounts has become
feasible. Present technologies are capable of identifying
lipids with different sum compositions (ie, phosphatidyl-
choline [PC] 34:1) [9], but more important is the identifi-
cation of molecular lipid species, (eg, PC 16:0/18:1) [10].
In the latter analysis, information of the type of fatty acids
and their positions attached to the glycerol backbone
making up the particular PC molecule is retrieved.
Furthermore, in the same analysis, it is now possible to
simultaneously determine the double bond positions of the
fatty acids, thus providing information of structurally
defined molecular lipid species (eg, PC 16:0/18:1n9)
[11￿]. Although similar information can be obtained by
traditional lipid analysis approaches, such as thin-layer
chromatography in combination with gas chromatography,
not only does it require much larger sample amounts and
more laborious sample preparation, but it does not deliver
the molecular lipid species.
The seminal work of Shinzawa-Itoh et al. [12￿] showed
that the oxygen transfer mechanism in cytochrome c
oxidase requires a specific phosphatidylglycerol molecular
lipid with palmitate and vaccenate at the sn-1 and sn-2
positions, respectively, on the glycerol backbone. In line
with other studies, this undoubtedly indicates that the lipid
structure is an essential determinant of the biological effect.
Therefore, molecular lipidomics is an essential asset and the
way forward to increase the biological knowledge of
molecular lipids and their mechanism of action, supporting
both basic research and pharmaceutical drug discovery and
development.
Among many lipid classes, the sphingolipids represent
a heterogeneous class of biomolecules that can be
defined by at least five different long-chain base moieties
in mammalian cells, more than 20 species of amide-
linked fatty acids, and around 500 different polar head
group structures [13, 14]. This level of molecular
complexity has been daunting, and therefore much of the
biological information still remains unknown. Recently, it
has been shown that sphingosine and ceramide promote
growth inhibition and apoptosis whereas sphingosine-1-
phosphate, ceramide-1-phosphate, and other sphingolipids
support cell survival, proliferation, differentiation, and
migration [15]. Indeed, dysfunctional sphingolipid metab-
olism has been implicated in numerous diseases including
diabetes, atherosclerosis, and hypertension, underscoring
the importance of lipid biochemistry for better under-
standing of the molecular basis of disease [16]. Finally,
others have recently unraveled the biological roles of
particular molecular sphingolipids, for instance showing
that C24-carbon to C26-carbon ceramides mediate the
death of a C. elegans mutant that fails to withstand
asphyxia, whereas ceramides with shorter chains have the
opposite effect [17].
Shotgun and Targeted Lipidomics
Proper sample storage, handling, and preparation are crucial
in the analytical process for avoiding artificial formation,
modification, or loss of lipid species. Therefore, typically
lipidomics is performed either by shotgun or targeted
approaches. In shotgun lipidomics, lipid extracts are infused
directly into a mass spectrometer whereby molecular lipids
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ion scans (PIS) and neutral loss scans (NLS) [18, 19]. The
major advantage of this approach is that hundreds of
molecular lipids, in nonseparated lipid extracts, can be
screened and accurately quantified in less than 30 min.
Thus, a simple sample extraction approach like Bligh and
Dyer [20], Ekroos [21], and Folch et al. [22]i sn o r m a l l y
sufficient for a thorough shotgun lipidomic analysis of
major lipids such as glycerophospholipids, ceramides,
glycerolipids, and sterol lipids (reviewed by Stahlman et
al. [2]), which undoubtedly minimizes sample cross-
contamination and possible errors originating from laborious
and time-consuming sample preparation. Despite the lack of
chromatographic preseparation, the selectivity and sensitivity
of the analysis are usually not hampered. Today, only a few
milligrams of tissue are required for the quantification of
hundreds of different molecular lipid species, thus making a
lipidome-wide scale analysis of not only whole tissues but
also small tissue subsections feasible (Table 1).
There are cases where molecular lipids require presepa-
ration prior to the mass spectrometric analysis. In such
circumstances, targeted lipidomics is preferred for enabling
the reliable retrieval of high qualitative data. In targeted
lipidomics, lipid extracts are separated by liquid chroma-
tography (LC), and eluted lipid species are monitored by
online mass spectrometry [23, 24]. Multiple reaction
monitoring (MRM) analysis offers both the high selectivity
and sensitivity necessary for quantification of low abundant
lipid species [25, 26]. In an optimized setting, the MRM
approach can offer the highest detection sensitivity possible
to date. However, due to the narrow time window of eluting
peaks, especially when using ultra high-performance LC
(UHPLC), only a restricted number of MRM transitions are
feasible when high qualitative and quantitative data are
called for. Thus, targeted lipidomics is best suited for
absolute quantification of only a select number of molec-
ular lipids that can be controlled by appropriate lipid
standards to minimize possible errors arising from changes
in the lipid ionization efficiency.
We believe that both shotgun and targeted lipidomics
are the best choices today for deciphering the molecular
lipidome comprehensively. Also, the quality and speci-
ficity of shotgun and targeted lipidomics are superior and
will meet any stringent regulatory quality standards when
set-up in the proper environment. In our laboratory, we
combine both approaches in parallel to gather the most
comprehensive and best quantitative information of the
lipidome achievable today. With these technologies, we
can currently quantify with high quality and high-
throughput up to 2,000 molecular lipids, depending on
the particular tissue-specific expression pattern (ie,
sample matrix). Simultaneously, these technologies have
been recently developed to suit the good laboratory
practice and regulatory environment, thus enabling
lipidomic analysis of clinical samples.
Biochemist-Friendly Bioinformatics
Despite the fact that lipidomics is thought of as another
“omics” technology, the type of data and information it
delivers is considerably different from transcriptomics and
proteomics. Measurement of lipid concentrations provides
phenotypic information about a state of an organism
determined by genetic regulation, functionality of protein
machinery, environmental factors, and diet. When a disease
or condition is studied, transcriptomics and proteomics will
indicate what genes or proteins are affected. Lipidomic
measurements, in turn, will bring to light the consequences
expressed by lipid concentration changes in biofluid and
tissue. Thus, lipidomics provides a readout that is closely
connected to the cause of the disease (eg, accumulation of
fatty substance in the arteries). It is noteworthy that
variations of lipid concentrations within and between
individuals are on par with usual clinical chemistry
measurements (Table 2).
A challenging task for biochemist/clinician-friendly
bioinformatics is to keep the simplicity of interpretation
of complex lipid profiles that can be obtained from
biofluids and tissues. The first level of analysis will
consist of correlating the profiles obtained from controls
and diseased or treated patients. Achieving the next
level of complexity where patterns of changes in lipid
concentrations can be related to specific genes and
pathways is more challenging. One approach requires
investigation of transcriptional profiles or proteomics
experiments conducted together with lipid profiles on
the same sample sets. The first attempts for conducting
such comparative analysis have been performed by
Laaksonen et al. [27] and Gieger et al. [28]. Another
approach is to predict affected metabolic functions from a
lipid profile itself. For example, involvement of elongases
can be predicted by analysis of a ratio of short-chain fatty
acids (FA) to long-chain FA. In a similar manner,
functionality of saturases/desaturases can be inferred
from ratio of lipids that contain FA with a different
saturation degree. A reasonable level of abstraction will
help to establish rapidly a framework for understanding
lipidomic data in a context of acute questions, such as
identification of novel noninvasively determined bio-
markers and better understanding of complex diseases.
With maturation of the bioinformatic approaches in
concert with analytical technologies, detailed character-
ization of lipid pathway-involving kinetic studies will
allow us to build more sophisticated models applicable to
mammals that are already available for lower organisms
[29￿].
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Plaque Biology
Atherosclerosis is a diffuse process of the vascular tree and
its development is characterized by the deposition of lipid
and blood-borne material to the artery walls. The disease
progression is normally slow and silent until the rupture of
a vulnerable plaque, causing potentially fatal vascular
events. Thus, early identification of individuals at risk is
challenging. To that end, sensitive biomarkers with good
specificity should be developed.
Table 1 Lipidomic platforms and their sample requirements for quantitative molecular species analysis
Platform Lipid class/molecule
a Typical sample amount required
Biofluid Tissue
Shotgun Cholesteryl ester (CE) 5 µL 1 mg
Free cholesterol (FC)
Lysophosphatidic acid (LPA)
Lysophosphatidylcholine (LPC)
Lysophosphatidylethanolamine (LPE)
Lysophosphatidylglycerol (LPG)
Lysophosphatidylinositol (LPI)
Lysophosphatidylserine (LPS)
Phosphatidic acid (PA)
Phosphatidylcholine (PC)
Phosphatidylethanolamine (PE)
Phosphatidylglycerol (PG)
Phosphatidylinositol (PI)
Phosphatidylserine (PS)
Sphingomyelin (SM)
Diacylglycerol (DAG)
Triacylglycerol (TAG)
Targeted ceramides Ceramide (Cer) 5 µL 5 mg
Glucosylceramide (GlcCer)
Galactosylceramide (GalCer)
Lactosylceramide (LacCer)
Sulfatide (SGalCer)
Targeted gangliosides Monosialoganglioside (GM) 100 µL 50–100 mg
Disialoganglioside (GD)
Trisialoganglioside (GT)
Quatrosialoganglioside (GQ)
Targeted eicosanoids Arachidonic acid (AA) 50–200 µL 20–100 mg
Leukotriene (LT)
Lipoxine (LX)
Thromboxane (TX)
Prostaglandine (PG)
Targeted sphingosines Sphingosine-1-phosphate (S1P) 50–100 µL 50–100 mg
Sphinganine-1-phosphate (SA1P)
Sphingosine (SPH)
Sphinganine (SPA)
Phytosphingosine (PSPH)
Ceramide-1-phosphate (Cer1P)
Targeted fatty acyl coenzyme A Fatty acyl coenzyme A (FA-CoA) 50–100 µL 50–100 mg
aEach lipid class consists of many molecular lipid species. Depending on the matrix, this may be more than 1,000 distinct species
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Uppsala Seniors (PIVUS) study, carotid plaques were
ultrasound characterized by size and echogenicity, which
are both predictors of cardiovascular events [30]. Com-
puterized analysis of carotid plaque size and echogenicity
were performed in a population-based manner in 1,016
individuals aged 70 years and compared with traditional
risk factors and markers of inflammation. Low high-
density lipoprotein (HDL), increased body mass index
(BMI), and decreased glutathione levels were associated
with the echolucency of carotid plaques, suggesting the
role of metabolic factors in plaque composition. On the
other hand, markers of inflammation were related to
plaque size alone, implying inflammation to be predom-
inantly associated with the degree of atherosclerosis. The
authors suggested that plaque size and echogenicity are
influenced by different risk factors.
Fagerberg et al. [31￿] studied the heterogeneous structure
of carotid atherosclerotic plaques aiming to relate blood
flow variations with differences in plaque morphology and
composition between sites located upstream and down-
stream of the maximum stenosis in symptomatic carotid
plaques. They observed that the location of maximum
stenosis relative to the carotid bifurcation varied consider-
ably between plaques. Furthermore, they reported that as
compared with the downstream side, the upstream side of
the stenosis had higher incidence of severe lesions with cap
rupture and intraplaque hemorrhage, more macrophages,
less smooth muscle cells, and more collagen.
The major implication of these findings to plaque
studies is that the intraplaque location may be an
important confounding factor and that different plaque
sections should be studied separately when assessing the
lipid building blocks of plaque specimens. We believe
that a thorough lipid analysis of atherosclerotic plaques
may expose novel markers for atherosclerotic develop-
ment and plaque rupture prediction. It seems necessary to
take the intraplaque location of different lipids into
account when analyzing the results of plaque lipidomic
screenings [34]. In the best-case scenario, plaque lipids
related either to vulnerability or disease development will
associate with the corresponding plasma lipid levels,
which naturally would increase the clinical utility of such
l i p i dm a r k e r s .P l a q u el i p i d o m i c sc a na l s ob eu s e dt os t u d y
cellular mechanisms and illuminate metabolic pathways
related to atherosclerosis, thereby facilitating drug target
identification. Current efforts with new drug targets such
as phospholipase A2 (PLA2)o ri n f l a m m a t o r ym e d i a t o r s
such as eicosanoids are likelyt ob e n e f i tf r o ml i p i d o m i c
analyses. In our preliminary analyses of human plaque
material, we have been able to identify and quantify more
than 900 different lipid species, equivalent in number (not
composition) to typically lipid-rich tissues such as liver
and brain.
Table 2 Select examples of lipidomic platform technical performance
Platform Lipid class Number of lipid species
detected in human plasma
Instrument CV, %
a Process CV, %
b
Shotgun Cholesteryl ester (CE) 25 3 21
Diacylglycerol (DAG) 24 4 9
Lysophosphatidylcholine (LPC) 10 2 7
Phosphatidylcholine (PC) 50 5 9
Ether-linked phosphatidylcholine (PC O) 66 1 12
Phosphatidylethanolamine (PE) 15 8 10
Ether-linked phosphatidylethanolamine (PE O) 24 9 15
Phosphatidylinositol (PI) 10 12 14
Phosphatidylserine (PS) 3 4 10
Sphingomyelin (SM) 42 4 9
Ceramides Ceramide (Cer) 8 15 10
Glucosylceramide (GlcCer) 6 10 7
Lactosylceramide (LacCer) 5 11 23
Sulfatide (SGalCer) 25 4 7
Total 313
Average 7 12
CV coefficient of variation
aThe instrument and process CV values are presented per lipid class. CV for instrument has been calculated from the same human plasma lipid extract
analyzed four times with each platform
bProcess CV has been calculated from same mouse brain sample extracted in triplicate
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Lipids are transported to the peripheral tissues and cells
and back to the liver by specific carrier particles called
lipoproteins. Measuring total levels of serum lipopro-
teins, LDL, or HDL has been accepted as an indicator of
ap e r s o n ’s coronary vascular disease (CVD) risk. How-
ever, serum fractionation is necessary for investigating
the individual properties and possible compositional
changes of lipoproteins in different disease states or after
a drug therapy. The most widely employed procedures
available for isolating serum lipoproteins include differ-
ent precipitation techniques, sequential flotation ultracen-
trifugation, size-exclusion gel chromatography, and
isopycnic density gradient ultracentrifugation. In recent
years, new techniques have arisen for studying the
distribution of lipoprotein subfractions that enable, for
example, the identification of highly atherogenic small
LDL particles [32].
The circulating lipoproteins are heterogenous in struc-
ture, shape, and size as well as intravascular metabolism.
HDL particles exhibit a number of antiatherogenic proper-
ties and play an important role in reverse cholesterol
transport (RCT). However, the protective activities of
HDL might vary between individuals and under different
disease states. For instance, in type 2 diabetes, the
endothelial vasoprotective effects of HDL have been shown
to be impaired compared with healthy subjects [33].
Moreover, in the study by Ansell et al. [34], HDL isolated
from patients with CVD possessed proinflammatory rather
than anti-inflammatory properties. Indeed, the lipidomics
approach was used to study the properties of small dense
HDL3 particles [35￿]. The authors demonstrated an elevated
sphingosine-1-phosphate to sphingomyelin (S1P/SM) ratio
as a feature of HDL3. Moreover, the S1P to SM ratio was
shown to correlate positively with antiapoptotic and
antioxidative properties of HDL subfractions.
Recently, Hiukka et al. [7] applied current lipidomics
technology to investigate the proatherogenic role of
apolipoprotein (apo)C-III and demonstrated that apoC-III–
enriched LDL from diabetes patients displayed an altered
lipid composition leading to increased susceptibility to the
proatherosclerotic sphingomyelinase.
Using immunoprecipitation approach, Bergmark et al.
[36] showed that lipoprotein(a) is a preferential carrier of
oxidized phospholipids in human plasma. Oxidized lipids
are known to play a role in signaling, apoptosis, platelet
aggregation, and induction of monocyte adhesion to
endothelial cells. Lipidomics can be used to study the
physiologic functions and mechanisms of atherogenicity of
proatherogenic lipoproteins and to investigate in detail the
structural changes induced in lipids under oxidative stress
conditions [37].
Animal Models and Translation
To study atherosclerotic plaque and different targeted
treatments, a model with good translational properties
should be used because the access to human atherosclerotic
plaque material is limited, particularly for interventional
studies. Lipidomics offer a new tool for disease model
selection as it allows detailed comparison of lipid building
blocks in plaques obtained from different available animal
models. We have compared the lipidomic profiles of the
human mammary artery and rat aorta (Laaksonen et al.,
unpublished data). The data, which are summarized in
Fig. 1, indicate that there is a substantial deviation already
at the lipid class level between human and rat material.
Moreover, detailed analysis of molecular lipid species
indicated that the number of recorded molecular lipids and
their molecular percentage distribution was quite different
between these sample sets. Thus, lipidomic profiling
indicated in this case that rat arteries are not a preferential
material to study human atherosclerosis due to differently
expressed lipids. The rat aorta lipidomics exemplifies the
potential of lipidomics for translational medicine.
Diagnostics and Treatment
Diagnostic Biomarkers of Atherosclerosis
CVD risk estimation is a difficult task despite improved
laboratory and imaging technologies. Traditionally LDL-C
and HDL-C measurements have been the cornerstones of
lipid-based CVD risk screening. These measures can
potentially be improved by direct measurements of apoA-I
and/or apoB. Recently, Martin et al. [38] demonstrated that
plasma apoB levels, but not LDL-C levels, were associated
with coronary artery calcification (CAC) scores in type 2
diabetes patients. Thus, they suggested that apoB levels
may be particularly useful in assessing the atherosclerotic
burden and cardiovascular risk in type 2 diabetes. However,
Ingelson et al. [39] recorded in a large, Framingham
population-based cohort that the overall performance of
apoB to apoA-I ratio for prediction of CVD was comparable
with that of traditional lipid ratios, with no incremental
utility over the ratio of total cholesterol to HDL-C.
Furthermore, modified LDL (ie, oxidized LDL [oxLDL])
has been shown to contribute to atherosclerosis develop-
ment, and that has prompted attempts to use circulating
oxLDL as a disease biomarker. Santos et al. [40] examined
the relationship of human immunoglobulin G (IgG) anti-
oxLDL antibodies with cardiovascular disease risk markers
in stable individuals and in patients with acute coronary
syndrome. They observed that acute inflammatory and
metabolic conditions decrease titers of human antibodies of
278 Curr Atheroscler Rep (2010) 12:273–281IgG class against oxLDL. They also suggested that
circulating anti-oxLDL antibodies could be associated with
a protective role in atherosclerosis.
Recently, non-hypothesis-driven metabolomic screenings
have been used for the identification of novel CVD
biomarkers. Zhang et al. [41] utilized an ultra-fast liquid
chromatography coupled with ion trap time-of-flight mass
spectrometry (UFLC/MS-IT-TOF) to study plasma and urine
metabolic profiles of atherosclerosis rats. Their observations
suggest that abnormal metabolism of phenylalanine, trypto-
phan, bile acids, and amino acids might be related to
atherosclerosis development. In addition, Zha et al. [42]
identified a metabolic fingerprint of 21 compounds in
hamsters that could be a potential marker for the development
of atherosclerosis.
Based on our unpublished data, it appears that lipido-
mics is able to deliver molecular lipids with a greater
diagnostic and prognostic value than LDL-C. Detailed
lipidomic information will also be useful in tailoring proper
treatments to the right patients, and in the best-case scenario
new targets may be revealed through pathway mapping
enabled by detailed molecular lipid information.
Lipidomics in Drug Trials: Measures of Efficacy and Safety
To date, lipidomics has not been exploited for the benefit of
clinical trials. As new and more precise CVD risk lipid
biomarkers are emerging, biochemical monitoring of drug
efficacy by traditional LDL-C and HDL-C assays will also
be enhanced. Interestingly, lipidomics is able to distinguish
the efficacy profiles of various members of a drug class
such as statins. In fact, the first attempts to use lipidomic
measurements to compare lipid-lowering profiles between
different statins have been performed [27, 43]. However,
these attempts have so far been more hypothesis generating
than informative, as the role of most of the molecular lipids
detected in these studies has yet to be established.
Indeed, our vision is that lipidomic analyses will play a
significant role in evaluating novel HDL-modulating com-
pounds such as cholesteryl ester transfer protein (CETP)
inhibitors. Furthermore, we suspect that current and new
LDL-C-lowering treatments and their combinations will be
carefully re-evaluated, as it is very likely that these
treatments trigger multiple changes in the lipoprotein
lipidome despite similar LDL-C-lowering effects.
Lipidomics has also proven to be an efficient way for
detecting adverse drug actions. So far, drug-induced liver
and muscle toxicities have been demonstrated in plasma
lipidomic profiles. The PC to phosphatidylethanolamine
(PE) ratio has been observed to reflect hepatocyte mem-
brane fluidity changes, allowing a sensitive measure for
liver toxicity [44]. Also, by taking advantage of the
molecular lipid information, the authors found new insight
into the mechanisms behind the membrane fluidity alter-
ations. We have reported earlier that a distinct plasma lipid
pattern can be used to monitor statin-induced gene
expression changes in human skeletal muscle and, thus, can
detect statin-induced muscle toxicity [27]. Our impression is
that this testing can be based on single molecular lipid
detection and that these toxicity biomarkers are more
sensitive than current markers including liver enzymes and
creatine kinase assays.
Fig. 1 Lipidomic analysis
conducted on human left inter-
nal mammary artery and rat
aorta samples show distinct
species-specific composition.
CE—cholesteryl esters;
DAG—diacylglycerols; PC—
phosphatidylcholines; PE—
phosphatidylethanolamines;
PS—phosphatidylserines;
SM—sphingomyelins
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It is apparent that the current lipidomics technology is
capable of adding a new dimension of detail and under-
standing to CVD studies. The CVD pathogenicity is
centered on lipid metabolism and the metabolic pathways.
The high-precision quantification of molecular lipids is a
necessity for deciphering the culprits in the involved
cascades. This will be accelerated by the increased
application and development of lipidomics technology.
Currently, lipidomics attempts to characterize structurally
defined molecular lipids from a single analysis [11￿] and
localize lipids in tissues such as aortic wall [45] and arterial
plaques [46]. Maturation of lipidomics and evolution of
new lipid-labeling techniques will not only improve
lipidome characterization, but also identify the deleterious
molecular lipids involved in the dysfunction, where this
occurs inside the organism and at what rate. Thus,
lipidomics is a prerequisite for advancing the CVD biology
and promoting the discovery of cardiovascular disease
biomarkers and new drug targets in coming years.
The pharmaceutical industry appears to be shifting gears,
moving from the blockbuster approach to more specialist
therapies. To be able to cater to a specialist group, care is
needed in identifying the correct patients that should
receive the medication at the correct time and correct dose.
Companion diagnostics, the very rare fruits of personalized
medicine, are the sought after tools. In a perfect world, the
drug developer would have access to the companion
diagnostic biomarker from early stages of research all the
way to post-marketing phase of the drug’s life cycle. The
requirements for these companion diagnostics are not only
the ability to identify those patients who will benefit from
the therapy (ie, the responders), but to also root out those
who are not tolerant of the treatment. Lipidomics offers
tools to address both the question of patient selection and
stratification as well as the ability to measure the treatment
efficacy and safety while taking the drug. To date, we have
only a handful of biomarkers employed as true companion
diagnostics, which regulatory authorities mandate to be
measured prior to drug administration, but none of these are
lipid based. The first clinical lipidomics applications will
likely be molecular lipid-based CVD risk markers and
screening methods that will better separate responders and
nonresponders both in clinical trials and clinical practice.
As lipidomics is taking an important role in the “omics”
hierarchy. We believe that molecular lipids, the tightly
regulated metabolic end-products, will provide an important
layer of phenotype information that will help us better
understand numerous gene–gene, gene–environment, and
gene–protein interactions that are involved in the develop-
ment of atherosclerosis; therefore, lipidomics will be one of
the cornerstones in the next generation of mechanistic
studies of disease. Finally, it is tempting to speculate on the
“theragnostic” potential of combining genomic, transcrip-
tomic, proteomic, and lipidomic data [47]. Although the
bioinformatic challenge is substantial, the lipidomic data
should be seen as booster for exploiting the strengths of all
“omics” in one holistic approach.
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